Market closedNon-fractional
Greenwich LifeSciences/GLSI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Greenwich LifeSciences
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.
Ticker
GLSI
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Stafford, United States
Employees
5
Website
greenwichlifesciences.com
GLSI Metrics
BasicAdvanced
$214M
Market cap
-
P/E ratio
-$0.72
EPS
3.34
Beta
-
Dividend rate
Price and volume
Market cap
$214M
Beta
3.34
Financial strength
Current ratio
14.132
Quick ratio
14.132
Management effectiveness
Return on assets (TTM)
-69.02%
Return on equity (TTM)
-109.97%
Valuation
Price to book
41.4
Price to tangible book (TTM)
41.44
Price to free cash flow (TTM)
-31.858
Growth
Earnings per share change (TTM)
15.86%
3-year earnings per share growth (CAGR)
50.84%
What the Analysts think about GLSI
Analyst Ratings
Majority rating from 1 analysts.
GLSI Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$2.4M
-11.11%
Profit margin
0.00%
NaN%
GLSI Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.17
-$0.13
-
-$0.21
-$0.19
Expected
-$0.23
-$0.23
-$0.22
-$0.20
-$0.20
Surprise
-28.26%
-43.48%
-
5.00%
-5.00%
GLSI News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Greenwich LifeSciences stock?
Greenwich LifeSciences (GLSI) has a market cap of $214M as of July 27, 2024.
What is the P/E ratio for Greenwich LifeSciences stock?
The price to earnings (P/E) ratio for Greenwich LifeSciences (GLSI) stock is 0 as of July 27, 2024.
Does Greenwich LifeSciences stock pay dividends?
No, Greenwich LifeSciences (GLSI) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Greenwich LifeSciences dividend payment date?
Greenwich LifeSciences (GLSI) stock does not pay dividends to its shareholders.
What is the beta indicator for Greenwich LifeSciences?
Greenwich LifeSciences (GLSI) has a beta rating of 3.34. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Greenwich LifeSciences stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.